Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

HBIO PEER ANALYSIS

Harvard Bioscience Inc — metric-by-metric comparison with peers and the industry median

HBIOHarvard Bioscience Inc

🇺🇸 USA · NASDAQ · Healthcare · Medical Instruments & Supplies

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Medical Instruments & Supplies

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
HBIOIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
HBIO+49.7%SEYKM+49.7%CTEC-13.4%
Year-to-Date (YTD)
HBIO-0.9%SEYKM-7.8%CTEC-6.8%
1-Year
Split-adjusted
HBIO+49.7%EMBC-65.0%KRMD+25.1%SMTI-15.0%UTMD+23.1%
Year-to-Date (YTD)
HBIO-0.9%EMBC-71.1%KRMD-21.0%SMTI+6.2%UTMD+24.5%

Key Metric Comparison

P/E

Lower is better
HBIO—SEYKM261.41CTEC34.07Median 35.66

ROE

Higher is better
HBIO-78.6%SEYKM0.7%CTEC10.9%Median 2.3%

Net Margin

Higher is better
HBIO-11.4%SEYKM1.3%CTEC7.2%Median 3.9%

Revenue Growth

Higher is better
HBIO-6.4%SEYKM-24.8%CTEC6.8%Median 6.4%

P/E

Lower is better
HBIO—EMBC1.77KRMD—SMTI—UTMD20.36Median 35.66

ROE

Higher is better
HBIO-78.6%EMBC—KRMD-13.7%SMTI-153.7%UTMD9.1%Median 2.3%

Net Margin

Higher is better
HBIO-11.4%EMBC10.7%KRMD-5.3%SMTI-31.2%UTMD28.9%Median 3.9%

Revenue Growth

Higher is better
HBIO-6.4%EMBC-3.4%KRMD23.3%SMTI17.4%UTMD-4.4%Median 6.4%

All Metrics

Valuation
MetricHBIOSEYKMCTECInd. Median
P/E—261.4134.07●35.66
P/B2.951.62●3.933.04
EV/EBITDA—410.4011.97●14.48
P/S0.35●3.462.442.85
Financial Health
MetricHBIOSEYKMCTECInd. Median
Current Ratio1.996.82●1.532.40
Debt/Equity439.2%0.0%●100.0%34.8%
NetDebt/EBITDA-19.80-168.37●2.331.44
Profitability
MetricHBIOSEYKMCTECInd. Median
Net Margin-11.4%1.3%7.2%●3.9%
ROE-78.6%0.7%10.9%●2.3%
ROA-12.4%0.6%4.8%●1.5%
EBITDA Margin-2.2%0.6%25.3%●13.8%
Growth + Dividend
MetricHBIOSEYKMCTECInd. Median
Rev. Growth-6.4%-24.8%6.8%●6.4%
NI Growth——-8.0%14.0%
Div. Yield—0.0%3.3%●1.7%
Payout—0.0%78.1%22.4%
Valuation
MetricHBIOEMBCKRMDSMTIUTMDInd. Median
P/E—1.77●——20.3635.66
P/B2.95-0.32●12.5831.691.833.04
EV/EBITDA—4.26●—30.928.1714.48
P/S0.350.19●4.922.075.882.85
Financial Health
MetricHBIOEMBCKRMDSMTIUTMDInd. Median
Current Ratio1.992.462.332.2828.64●2.40
Debt/Equity439.2%-216.9%●19.9%688.1%0.2%34.8%
NetDebt/EBITDA-19.80●3.643.684.17-5.331.44
Profitability
MetricHBIOEMBCKRMDSMTIUTMDInd. Median
Net Margin-11.4%10.7%-5.3%-31.2%28.9%●3.9%
ROE-78.6%—-13.7%-153.7%9.1%●2.3%
ROA-12.4%10.4%●-8.2%-40.5%8.8%1.5%
EBITDA Margin-2.2%30.9%-3.4%7.7%43.6%●13.8%
Growth + Dividend
MetricHBIOEMBCKRMDSMTIUTMDInd. Median
Rev. Growth-6.4%-3.4%23.3%●17.4%-4.4%6.4%
NI Growth—114.8%●——-16.3%14.0%
Div. Yield—17.9%●——1.7%1.7%
Payout—31.5%——36.5%22.4%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on HBIO

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.